ACSL5: A Potential Drug Target and Biomarker for Fatty Acid Coenzyme A Ligase 5

Target Name: ACSL5

NCBI ID: G51703

ACSL5

ACSL5: A Potential Drug Target and Biomarker for Fatty Acid Coenzyme A Ligase 5

Fatty acid coenzyme A ligase 5 (ACSL5) is a protein that plays a crucial role in the metabolism of fatty acids, which are essential for various cellular functions. ACSL5 is a member of the superfamily of Coenzyme A ligases and is highly conserved across various species . It is expressed in various tissues and cells, including liver, muscle, and pancreatic beta cells, and is involved in the catalytic activity of fatty acid Coenzyme A ligase, which is a key enzyme in the citric acid cycle (also known as the Krebs cycle or TCA cycle).

The citric acid cycle is a central metabolic pathway that generates energy from food via the breakdown of fatty acids. The ACSL5 enzyme plays a crucial role in the conversion of fatty acids to produce energy. It is the rate-limiting step in the citric acid cycle and is responsible for the production of the high-energy electrons that are used to power cellular processes.

ACSL5 is a protein that consists of 1,122 amino acids and has a calculated molecular mass of 18.05 kDa. It has a characteristic Rossmann-fold structure that is characteristic of proteins that are involved in enzyme-catalytic activities. The Rossmann-fold is a structural motif that is composed of a specific arrangement of amino acids that is responsible for the stability and active site stability of the enzyme.

Several studies have identified potential drug targets for ACSL5. One of the main targets is the inhibition of ACSL5 has been shown to be effective in treating various diseases, including obesity, type 2 diabetes, and heart disease. This is because ACSL5 is involved in the metabolism of fatty acids, which are a major source of energy for these diseases.

Another potential drug target for ACSL5 is the inhibition of ACSL5 has been shown to be effective in treating various types of cancer, including breast, ovarian, and prostate cancer. This is because ACSL5 is involved in the metabolism of fatty acids, which are often abnormally expressed in cancer cells.

In addition to its potential as a drug target, ACSL5 has also been identified as a potential biomarker for various diseases. The production of high-energy electrons by ACSL5 is often reduced in diseases, such as cancer, obesity, and type 2 diabetes. This reduction in energy production can lead to the accumulation of fatty acids in the body, which can be used as a diagnostic biomarker for these diseases.

Overall, ACSL5 is a protein that plays a crucial role in the metabolism of fatty acids and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of ACSL5 in the biology of diseases and to develop effective treatments.

Protein Name: Acyl-CoA Synthetase Long Chain Family Member 5

Functions: Catalyzes the conversion of long-chain fatty acids to their active form acyl-CoAs for both synthesis of cellular lipids, and degradation via beta-oxidation (PubMed:17681178, PubMed:24269233, PubMed:22633490). ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage (By similarity). Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids (By similarity). It was suggested that it may also stimulate fatty acid oxidation (By similarity). At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells

The "ACSL5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACSL5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets